Incannex Healthcare Inc. (IXHL): R&D Expense
$10.75M
Year ended 2025-06-30
$7.42M
Trailing 12 months to 2026-03-31
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $10.75M | -16.6% | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | $12.88M | +104.1% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $6.31M | n/a | 2024-09-30, From 2022-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $21.12M | -29.7% |
| iBio, Inc. (IBIO) | 2026-06-30 | $19.64M | +136.3% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
Compare IXHL, ATNM, IBIO, SILO side by side · Screen every company in Pharmaceutical Preparations ↗